Medicines Co. (MDCO) Reports Q2 Loss of $1.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company (MDCO) PT Lowered to $54 at Jefferies Following 2Q
August 10, 2017 8:56 AM EDTJefferies lowered its price target on The Medicines Company (NASDAQ: MDCO) to $54.00 (from $62.00) while maintaining a Buy rating. MDCO reported 2Q17 EPS of ($5.52) vs the consensus of ($1.47). This difference was due to the withdrawal of IONSYS from the market and discontinuation of the... More
The Medicines Company (MDCO) PT Lowered to $54 at Cowen; Reiterates Outperform
August 10, 2017 7:37 AM EDTCowen lowered its price target on The Medicines Company (NASDAQ: MDCO) to $54.00 (from $61.00) while maintaining a Outperform rating. Continued portfolio streamlining heightens the concentration of value on Inclisiran. Phase 3 studies getting underway in 2H17 will read out in 2H19.
The Phase III... More
